SHR3824
Sponsors
Jiangsu HengRui Medicine Co., Ltd.
Conditions
Hepatic ImpairmentRenal Insufficiency,Type 2 DiabetesType 2 DiabetesType 2 Diabetes Mellitus
Phase 1
Pharmacodynamics, Pharmacokinetics, Safety and Tolerability of SHR3824 in Type 2 Diabetes Mellitus Patients
CompletedNCT02346175
Start: 2014-06-30End: 2014-12-31Updated: 2015-02-03
Effect of a High-fat Meal on the Pharmacokinetics of SHR3824 and Mass Balance Study in Healthy Subjects
CompletedNCT02353975
Start: 2014-05-31End: 2014-09-30Updated: 2015-02-03
The PK/PD Study of Single Dose of SHR3824 in Healthy Volunteers
CompletedNCT02356224
Start: 2013-06-30End: 2013-12-31Updated: 2015-02-05
The PK/PD Study of Multiple Dose of SHR3824 in Healthy Volunteers
CompletedNCT02361138
Start: 2013-12-31End: 2014-05-31Updated: 2015-02-11
The PK/PD, Efficacy, Safety and Tolerability Study of SHR3824 in Combination With Metformin in Type 2 Diabetes Mellitus Patients
NCT02366377
Start: 2015-02-28Target: 168Updated: 2015-02-19
The PK/PD, Efficacy, Safety and Tolerability Study of SHR3824 in Type 2 Diabetes Mellitus Patients
NCT02366351
Start: 2015-02-28Target: 168Updated: 2015-02-19
Safety and Pharmacokinetics/Pharmacodynamics of SHR3824 in Patients With Hepatic Impairment
NCT03160014
Start: 2015-06-30End: 2017-12-31Target: 32Updated: 2017-05-19
Safety and Pharmacokinetics/Pharmacodynamics of SHR3824 in Type 2 Diabetes Patients With Renal Insufficient
NCT03159832
Start: 2015-06-30End: 2017-12-31Target: 24Updated: 2017-05-19
Phase 3
Efficacy and Safety of SHR3824 as Monotherapy in Subjects With Type 2 Diabetes
NCT03159052
Start: 2017-06-30End: 2019-06-30Target: 450Updated: 2017-05-18
Efficacy and Safety of SHR3824 in Combination With Metformin in Subjects With Type 2 Diabetes
NCT04390295
Start: 2017-11-02End: 2020-05-31Target: 450Updated: 2020-05-15